The European Medicines Agency (EMA) has begun evaluating an application for Comirnaty booster dose (BioNTech / Pfizer vaccine) for adolescents aged 12 to 15 years. The application is also in progress for older adolescents aged 16 to 17 years.
Booster doses in vaccinated people (ie in people who have completed their initial vaccination) are given to restore protection after it has weakened. Comirnaty boosters may be given to people 18 years of age or older at present.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) will conduct a rapid review of data submitted by Comirnaty’s trading company, including real-world results from Israel.
SOURCE: ΑΠΕ-ΜΠΕ
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
